FDA's Gottlieb Pushing 'Seamless' Clinical Trials For Faster Development
US FDA Commissioner notes that combined-phase clinical trials could be expanded beyond oncology as one way of reducing drug development costs.
You may also be interested in...
A Pink Sheet analysis illustrates how the outgoing commissioner enhanced FDA's ability to facilitate the further development of innovative drugs.
US FDA will continue expanded access activities as government shutdown continues, but CDER Director Woodcock says that platform trials can help eliminate the need for expanded access to exist.
US FDA Commissioner Gottlieb says common diseases need new treatments and argues streamlining trials may pique industry interest.